Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India
Subscribe To Our Newsletter & Stay Updated